broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K81473043-001-19-5 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 1.432659 | 0.423021 | 0.191935 | 1 | 0.006934 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-001307 |
BRD-K82135108-001-04-3 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.282411 | 1.567596 | 0.677021 | 0.649902 | 0.087861 | 0.149381 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-001307 |
BRD-K82746043-001-19-3 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.360176 | 2.431418 | 0.684121 | 0.841397 | 0.903152 | 1.525318 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-001307 |
BRD-K82818427-001-04-8 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.823352 | -0.115444 | -0.095818 | 0.922721 | 0.008364 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-001307 |
BRD-K83029223-001-01-3 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.470304 | 3.419897 | 0.377191 | 0.763974 | 0.008275 | 0.018894 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-001307 |
BRD-K83988098-001-02-0 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 32.712752 | 0.830176 | -0.0727 | 1 | 38,885,354.879701 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-001307 |
BRD-K85402309-043-01-9 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.057088 | 2.597821 | 0.391634 | 0.940366 | 5.907212 | 6.189431 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-001307 |
BRD-K85606544-001-09-1 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.710723 | -0.902378 | 0.138417 | 0.938279 | 0.004021 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-001307 |
BRD-K86118762-001-01-8 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 1.492221 | 1.465023 | 0.568641 | 1 | 1.276514 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-001307 |
BRD-K86972824-001-01-4 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.827255 | -0.387862 | -0.045391 | 0.964887 | 0.000996 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-001307 |
BRD-K87737963-001-06-0 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 1.413596 | 1.97011 | 0.41623 | 1 | 0.263257 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-001307 |
BRD-K87782578-001-01-4 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 1.238104 | 0.428012 | 0.087697 | 1 | 3.16844 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-001307 |
BRD-K87909389-003-03-4 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.160675 | 1.484739 | 0.819372 | 0.677123 | 0.239761 | 0.31129 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001307 |
BRD-K88510285-001-17-8 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.092515 | 5.288798 | 0.835208 | 0.589505 | 0.031053 | 0.032278 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-001307 |
BRD-K89014967-001-04-3 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.830751 | -3.472947 | 0.234843 | 0.881213 | 0.55385 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-001307 |
BRD-K92441787-001-04-1 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.9673 | -4.656525 | -0.016882 | 0.975376 | 0.91016 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-001307 |
BRD-K92723993-001-17-4 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 2.768373 | 1.604661 | 0.09977 | 1 | 26.495149 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-001307 |
BRD-K95142244-001-01-5 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 2.600777 | 0.231318 | 0.008882 | 1 | 44.810456 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-001307 |
BRD-K96123349-236-02-8 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 1.177135 | 0.066469 | 0.003975 | 1 | 1.353985 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-001307 |
BRD-K98572433-001-02-9 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 1.595614 | 4.509161 | 0.531116 | 1 | 0.48572 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-001307 |
BRD-K99113996-001-02-0 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.583721 | 3.668676 | 0.331251 | 0.949138 | 3.066062 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-001307 |
BRD-K99616396-001-05-1 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 0.960874 | -1.437294 | -0.011165 | 0.980425 | 0.078332 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-001307 |
BRD-K99749624-001-07-0 | ACH-001307 | 8505C_THYROID | MTS010 | 1 | 1.25939 | 0.118343 | 0.039932 | 1 | 0.095355 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-001307 |
BRD-A25234499-001-19-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.012248 | -0.015101 | -0.015201 | 1 | 29.102543 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-001318 |
BRD-A70858459-001-01-7 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.820749 | 2.320564 | 0.066022 | 0.945923 | 0.535455 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-001318 |
BRD-A74914197-001-02-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.803623 | 3.356054 | -0.036033 | 0.830551 | 0.000144 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-001318 |
BRD-K02113016-001-19-6 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.88072 | 1.357561 | 0.014814 | 0.88917 | 0.00084 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-001318 |
BRD-K02130563-001-11-4 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.181256 | 2.240737 | 0.809143 | 0.478178 | 0.020593 | 0.025177 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-001318 |
BRD-K03390685-001-01-7 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.06637 | -0.44927 | -0.065324 | 1 | 0.010029 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-001318 |
BRD-K03406345-001-21-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.470757 | -2.469005 | 0.137109 | 0.987418 | 0.000548 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001318 |
BRD-K03449891-001-08-6 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.265922 | 3.893701 | 0.425409 | 0.9708 | 7.25129 | 8.81185 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-001318 |
BRD-K03765900-001-01-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.171261 | 0.419212 | 0.474727 | 0.710748 | 0.549031 | 1.492892 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-001318 |
BRD-K05804044-001-18-5 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.968826 | -0.123902 | -0.021136 | 0.976072 | 1,556.630403 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-001318 |
BRD-K06814349-304-02-7 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.666753 | 5.070333 | 0.477358 | 0.918619 | 0.934869 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-001318 |
BRD-K08109215-001-06-4 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.824575 | -1.876183 | -0.166364 | 0.896279 | 0.189405 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-001318 |
BRD-K08542803-001-02-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.079733 | 6.826224 | 0.57921 | 0.829983 | 1.664752 | 1.707662 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-001318 |
BRD-K08547377-001-04-4 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.007403 | 0.258001 | -0.176635 | 1 | 0.023367 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-001318 |
BRD-K08703257-001-13-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.985341 | 0.518348 | -0.124368 | 0.990788 | 0.017675 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-001318 |
BRD-K08799216-001-05-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.359028 | 7.308773 | 0.729942 | 0.890258 | 1.898452 | 2.257532 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-001318 |
BRD-K09951645-001-11-8 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.995748 | -0.235501 | -0.020518 | 0.997527 | 0.366331 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-001318 |
BRD-K11267252-001-05-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.430507 | 0.442203 | 0.04648 | 1 | 59.292033 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-001318 |
BRD-K11630072-001-13-2 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.625837 | 2.46764 | 0.21227 | 0.905573 | 0.864503 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-001318 |
BRD-K12184916-001-19-6 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.299491 | 0.727419 | 0.338525 | 0.49805 | 0.007681 | 0.026976 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-001318 |
BRD-K12343256-001-14-7 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.111275 | -0.124356 | -0.019574 | 1 | 47.914521 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-001318 |
BRD-K13049116-001-04-0 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.002404 | -0.224333 | -0.012747 | 1 | 0.516521 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-001318 |
BRD-K13390322-001-06-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.103842 | 13.192374 | 0.73253 | 0.807752 | 1.246956 | 1.269154 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-001318 |
BRD-K13514097-001-04-6 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | -0.022306 | 0.026965 | 0.07441 | 0.449999 | 0.000273 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-001318 |
BRD-K13662825-001-07-5 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.071303 | 4.917295 | 0.828583 | 0.569791 | 0.027938 | 0.028826 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-001318 |
BRD-K14109347-001-03-4 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.264636 | 0.887775 | 0.706837 | 0.773719 | 0.54656 | 1.277125 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-001318 |
BRD-K15179879-001-03-2 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.183056 | 4.157457 | 0.850992 | 0.50672 | 0.028519 | 0.031824 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-001318 |
BRD-K15600710-066-05-8 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.056476 | 0.71445 | 0.383162 | 0.755765 | 1.01848 | 1.204483 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-001318 |
BRD-K16730910-001-10-7 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.819826 | 4.085582 | 0.114222 | 0.910199 | 0.079315 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-001318 |
BRD-K17555800-003-02-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.86616 | 1.195199 | -0.008808 | 0.971922 | 1.409727 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-001318 |
BRD-K17610631-001-03-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.326917 | -0.045601 | -0.052042 | 1 | 0.055513 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-001318 |
BRD-K17743125-001-08-4 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.101351 | 7.68991 | 0.72719 | 0.818551 | 1.40929 | 1.45143 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-001318 |
BRD-K17894950-001-14-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.790162 | 0.015675 | -0.032909 | 0.889115 | 0.000055 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-001318 |
BRD-K18961567-001-01-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.00315 | 0.198547 | -0.000775 | 1 | 0.172958 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-001318 |
BRD-K19540840-001-09-4 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.775995 | 0.184746 | 0.034529 | 0.860308 | 0.004256 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-001318 |
BRD-K19687926-001-04-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.251425 | 0.69572 | 0.048746 | 0.873757 | 3.372233 | 9.208192 | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-001318 |
BRD-K19796430-001-05-6 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.800807 | 2.046774 | 0.077983 | 0.836383 | 0.003403 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-001318 |
BRD-K22064724-001-01-8 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.099104 | 5.934747 | 0.656885 | 0.725629 | 0.520481 | 0.540224 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-001318 |
BRD-K22822991-001-02-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.555299 | 0.738985 | -0.048334 | 0.791452 | 0.107401 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-001318 |
BRD-K23228615-001-02-8 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.300847 | 1.256315 | 0.654126 | 0.708858 | 0.176525 | 0.3673 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-001318 |
BRD-K23984367-001-07-5 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.835907 | 0.251851 | 0.048807 | 0.926664 | 0.201684 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-001318 |
BRD-K26026438-001-01-0 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.187102 | 0.476412 | 0.602921 | 0.727993 | 0.581922 | 1.556524 | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-001318 |
BRD-K26657438-001-15-2 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.836762 | 0.622516 | 0.162495 | 0.891136 | 0.012637 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-001318 |
BRD-K28822270-001-03-7 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.235315 | 4.342595 | 0.835142 | 0.785549 | 0.688359 | 0.796942 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-001318 |
BRD-K29905972-001-06-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.660226 | 4.379005 | 0.09487 | 0.83381 | 0.086802 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-001318 |
BRD-K30577245-001-05-0 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.43174 | 3.206999 | 0.561422 | 0.726335 | 0.005835 | 0.010856 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-001318 |
BRD-K31698212-001-02-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.899341 | 0.62862 | 0.055405 | 0.949208 | 0.07437 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-001318 |
BRD-K31928526-001-02-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.936868 | -2.270481 | -0.086471 | 0.96829 | 0.079852 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-001318 |
BRD-K33379087-001-07-5 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.462579 | 2.654013 | 0.48748 | 0.844657 | 0.605111 | 1.607105 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-001318 |
BRD-K33610132-001-02-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.760148 | 5.601325 | 0.288871 | 0.930155 | 0.592505 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-001318 |
BRD-K33622447-066-01-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.037534 | -0.095309 | -0.018041 | 1 | 1.117573 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-001318 |
BRD-K35520305-001-16-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.02197 | -0.01701 | -0.010416 | 1 | 28,929,927.935795 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-001318 |
BRD-K36627727-001-05-4 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.802193 | 0.302354 | -0.032373 | 0.881294 | 0.016221 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-001318 |
BRD-K36788280-001-01-2 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.870299 | 0.974536 | 0.160163 | 0.945043 | 0.166112 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-001318 |
BRD-K37379014-001-02-0 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.158667 | 0.25901 | 0.29441 | 0.517643 | 0.000337 | 0.001471 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-001318 |
BRD-K38332599-001-01-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.573107 | 0.435955 | 0.532749 | 0.824427 | 0.235881 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-001318 |
BRD-K38527262-300-01-0 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.899047 | 2.275746 | 0.100034 | 0.967387 | 0.156831 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-001318 |
BRD-K38852836-001-02-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.103626 | 3.177466 | 0.808158 | 0.579228 | 0.026313 | 0.028309 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-001318 |
BRD-K39974922-001-04-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.732978 | 0.955483 | 0.156713 | 0.934747 | 1.045704 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-001318 |
BRD-K41859756-001-06-8 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.123167 | 13.346027 | 0.922437 | 0.487766 | 0.008642 | 0.008827 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-001318 |
BRD-K42495768-001-01-7 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.140187 | 0.260075 | -0.073747 | 1 | 0.038301 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-001318 |
BRD-K42805893-001-04-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.65649 | 1.968259 | 0.285165 | 0.802187 | 0.037401 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-001318 |
BRD-K42828737-001-03-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.21988 | -3.376555 | 0.579105 | 1 | 0.059874 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-001318 |
BRD-K42898655-001-01-8 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.389926 | 1.056883 | 0.766922 | 0.571082 | 0.00065 | 0.002721 | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-001318 |
BRD-K43389675-001-02-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.168696 | 1.564325 | 0.97604 | 0.53856 | 0.045736 | 0.059501 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-001318 |
BRD-K44227013-001-06-4 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.29002 | 3.888688 | 0.514155 | 0.90122 | 2.595365 | 3.244121 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-001318 |
BRD-K44827188-001-06-0 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.829765 | 0.504526 | 0.004873 | 0.897512 | 0.023805 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-001318 |
BRD-K46386702-001-02-1 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.40249 | 0.403673 | 0.479999 | 0.73618 | 0.166384 | 9.544686 | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-001318 |
BRD-K49328571-001-15-0 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.743915 | 0.077637 | -0.010424 | 0.846831 | 0.000439 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-001318 |
BRD-K49350383-001-14-5 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 2.129477 | 0.75277 | 0.673044 | 1 | 0.565481 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-001318 |
BRD-K50010139-001-01-5 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.249404 | 0.168572 | 0.076734 | 0.590919 | 0.025235 | 1.519288 | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-001318 |
BRD-K50168500-001-07-9 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 1.015238 | 0.513874 | -0.008871 | 1 | 0.645985 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-001318 |
BRD-K51313569-001-07-8 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.777587 | 0.257198 | -0.0883 | 0.842941 | 0.001724 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-001318 |
BRD-K51791723-003-01-7 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.234179 | 3.529859 | 0.564658 | 0.849867 | 1.492437 | 1.784956 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001318 |
BRD-K51967704-001-03-6 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.099073 | 11.848572 | 0.902333 | 0.721814 | 0.499579 | 0.508977 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-001318 |
BRD-K52313696-001-12-3 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.779121 | -0.000359 | -0.000109 | 0.889532 | 0.327448 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-001318 |
BRD-K53414658-001-08-2 | ACH-001318 | PLCPRF5_LIVER | MTS010 | 1 | 0.613997 | 0.904054 | 0.720022 | 0.829061 | 0.138004 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-001318 |
Subsets and Splits